Literature DB >> 23886860

Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment.

Jason R Clapper1, Michelle D Hendricks, Guibao Gu, Carrie Wittmer, Carrie S Dolman, John Herich, Jennifer Athanacio, Christiane Villescaz, Soumitra S Ghosh, Joseph S Heilig, Carolyn Lowe, Jonathan D Roth.   

Abstract

Shortcomings of previously reported preclinical models of nonalcoholic steatohepatitis (NASH) include inadequate methods used to induce disease and assess liver pathology. We have developed a dietary model of NASH displaying features observed clinically and methods for objectively assessing disease progression. Mice fed a diet containing 40% fat (of which ∼18% was trans fat), 22% fructose, and 2% cholesterol developed three stages of nonalcoholic fatty liver disease (steatosis, steatohepatitis with fibrosis, and cirrhosis) as assessed by histological and biochemical methods. Using digital pathology to reconstruct the left lateral and right medial lobes of the liver, we made comparisons between and within lobes to determine the uniformity of collagen deposition, which in turn informed experimental sampling methods for histological, biochemical, and gene expression analyses. Gene expression analyses conducted with animals stratified by disease severity led to the identification of several genes for which expression highly correlated with the histological assessment of fibrosis. Importantly, we have established a biopsy method allowing assessment of disease progression. Mice subjected to liver biopsy recovered well from the procedure compared with sham-operated controls with no apparent effect on liver function. Tissue obtained by biopsy was sufficient for gene and protein expression analyses, providing the opportunity to establish an objective method of assessing liver pathology before subjecting animals to treatment. The improved assessment techniques and the observation that mice fed the high-fat diet exhibit many clinically relevant characteristics of NASH establish a preclinical model for identifying pharmacological interventions with greater likelihood of translating to the clinic.

Entities:  

Keywords:  fibrosis; in vivo tissue sampling; nonalcoholic fatty liver disease; steatohepatitis; steatosis

Mesh:

Substances:

Year:  2013        PMID: 23886860     DOI: 10.1152/ajpgi.00079.2013

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  107 in total

1.  Liver-specific loss of lipin-1-mediated phosphatidic acid phosphatase activity does not mitigate intrahepatic TG accumulation in mice.

Authors:  George G Schweitzer; Zhouji Chen; Connie Gan; Kyle S McCommis; Nisreen Soufi; Roman Chrast; Mayurranjan S Mitra; Kui Yang; Richard W Gross; Brian N Finck
Journal:  J Lipid Res       Date:  2015-02-26       Impact factor: 5.922

2.  Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.

Authors:  David J Orlicky; Andrew E Libby; Elise S Bales; Rachel H McMahan; Jenifer Monks; Francisco G La Rosa; James L McManaman
Journal:  J Physiol       Date:  2019-01-02       Impact factor: 5.182

3.  Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution.

Authors:  Joel T Haas; Luisa Vonghia; Denis A Mogilenko; An Verrijken; Olivier Molendi-Coste; Sébastien Fleury; Audrey Deprince; Artemii Nikitin; Eloïse Woitrain; Lucie Ducrocq-Geoffroy; Samuel Pic; Bruno Derudas; Hélène Dehondt; Céline Gheeraert; Luc Van Gaal; Ann Driessen; Philippe Lefebvre; Bart Staels; Sven Francque; David Dombrowicz
Journal:  Nat Metab       Date:  2019-06-14

Review 4.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

5.  Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.

Authors:  Maria Nicoline Baandrup Kristiansen; Sanne Skovgård Veidal; Kristoffer Tobias Gustav Rigbolt; Kirstine Sloth Tølbøl; Jonathan David Roth; Jacob Jelsing; Niels Vrang; Michael Feigh
Journal:  World J Hepatol       Date:  2016-06-08

Review 6.  Preclinical models of non-alcoholic fatty liver disease.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Arun J Sanyal
Journal:  J Hepatol       Date:  2017-11-09       Impact factor: 25.083

7.  Hepatic glucose uptake and disposition during short-term high-fat vs. high-fructose feeding.

Authors:  Katie C Coate; Guillaume Kraft; Mary Courtney Moore; Marta S Smith; Christopher Ramnanan; Jose M Irimia; Peter J Roach; Ben Farmer; Doss W Neal; Phil Williams; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-05-27       Impact factor: 4.310

8.  Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD).

Authors:  Xunjun Ni; Haiyan Wang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

9.  Long-term intake of 9-PAHPA or 9-OAHPA modulates favorably the basal metabolism and exerts an insulin sensitizing effect in obesogenic diet-fed mice.

Authors:  Melha Benlebna; Laurence Balas; Béatrice Bonafos; Laurence Pessemesse; Gilles Fouret; Claire Vigor; Sylvie Gaillet; Jacques Grober; Florence Bernex; Jean-François Landrier; Ondrej Kuda; Thierry Durand; Charles Coudray; François Casas; Christine Feillet-Coudray
Journal:  Eur J Nutr       Date:  2020-09-28       Impact factor: 5.614

10.  Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice.

Authors:  Shai Fuchs; Bernardo Yusta; Laurie L Baggio; Elodie M Varin; Dianne Matthews; Daniel J Drucker
Journal:  JCI Insight       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.